Targeting HRAS in R/M Head and Neck Cancer

Targeting HRAS in R/M Head and Neck Cancer

Despite advances in the management of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) and the introduction of immune...

An Awareness of Delayed irAEs After Anti-PD1 Therapy is Needed

An Awareness of Delayed irAEs After Anti-PD1 Therapy is Needed

Immune checkpoint inhibitors (ICIs) have changed the treatment armamentarium and prognosis for many cancers, including melanoma. However, by interfering with the pathways...

FDA Cancer Therapy Approvals in March 2021

FDA Cancer Therapy Approvals in March 2021

In March, the US Food and Drug Administration (FDA) granted six new indications to immunotherapy and targeted therapy for solid and hematological...

Lenvatinib/Pembrolizumab Combo Justified for Endometrial Cancer

Lenvatinib/Pembrolizumab Combo Justified for Endometrial Cancer

The prognosis for patients with advanced or recurrent endometrial cancer is poor. Until recently, the treatment options after progression on first-line, platinum-based...

The Clinical Utility of Genomic Testing in Advanced Solid Tumors

The Clinical Utility of Genomic Testing in Advanced Solid Tumors

Developments in next-generation sequencing (NGS) and other molecular profiling technologies are facilitating precision medicine for patients with advanced cancer, leading to improved...

Fecal Microbiota Transplant for Immunotherapy-Refractory Melanoma

Fecal Microbiota Transplant for Immunotherapy-Refractory Melanoma

Immunotherapy with immune checkpoint inhibitors (ICI) is the standard of care for advanced melanoma, although only around 40% of patients achieve durable...